Primary resistance to integrase inhibitors in Shenzhen
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkac442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Yue Zhu und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Shantou University, Shantou, China. Hauptthemen laut MEDLINE: Anti-HIV Agents, Drug Resistance, Viral, HIV Infections, HIV Integrase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China, Shenzhen Key Medical Discipline Construction Fund.
Abstract (Originalsprache)
Objectives
In recent years, integrase strand transfer inhibitor (INSTI)-containing regimens have been increasingly adopted in treatment for HIV/AIDS and promoted as non-occupational post-exposure prophylaxis in China. This study aims to describe the prevalence of resistance to integrase and drug resistance mutations (DRMs) among ART-naive patients in Shenzhen, China.
Methods
Serum samples and demographic information were collected from newly reported ART-naive patients in Shenzhen in 2020. The study sequenced the coding sequence of the HIV-1 integrase gene and determined the DRMs. Results In this study, 1682 newly reported cases were included and 1071 of them were successfully sequenced finally. The prevalence of primary drug resistance was 1.77%, with 19 samples showing varying degrees of resistance to INSTIs. The study detected six major DRMs in 16 individuals and eight accessory DRMs in 24 individuals. The prevalence of transmitted drug resistance (TDR) mutations was 1.21%, with five transmitted mutations detected in 13 individuals. The prevalence of drug resistance to raltegravir and elvitegravir was statistically higher than to bictegravir, cabotegravir and dolutegravir.
Conclusions
The prevalence of INSTI resistance in Shenzhen in 2020 was relatively high. Continued surveillance for resistance to INSTIs is recommended and treatment regimens should be adopted based on the pattern of resistance to INSTIs. Dolutegravir or bictegravir is first recommended when considering INSTIs as treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Public Health, Shantou University, Shantou, China.
- Department of HIV/AIDS Control and Prevention, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
- School of Public Health, Shanxi Medical University, Taiyuan, China.
- School of Public Health, University of South China, Hengyang, China.
- Department of Infectious Diseases, The Third People's Hospital of Shenzhen, Shenzhen, China.
ORCID-Profile: Jin Zhao
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
- Shenzhen Key Medical Discipline Construction Fund
Zitieren
APA
Zhu, Y., Huang, Y., Zheng, C., Tang, J., Zeng, G., Xie, W., Wang, H., Zhang, L., Liu, S., Zhang, Y., Tan, W., Tan, J., Jiang, L., He, Y., Xu, L., Yang, Z., & Zhao, J. (2023). Primary resistance to integrase inhibitors in Shenzhen. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac442
Vancouver
Zhu Y, Huang Y, Zheng C, Tang J, Zeng G, Xie W, et al. Primary resistance to integrase inhibitors in Shenzhen. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac442
BibTeX
@article{Zhu2023,
author = {Zhu, Yue and Huang, Yuanmei and Zheng, Chenli and Tang, Jie and Zeng, Guang and Xie, Wei and Wang, Hui and Zhang, Lukun and Liu, Shaochu and Zhang, Yan and Tan, Wei and Tan, Jingguang and Jiang, Lijuan and He, Yun and Xu, Liumei and Yang, Zhengrong and Zhao, Jin},
title = {Primary resistance to integrase inhibitors in Shenzhen},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkac442}
}
EUVIMED